Boehringer Ingelheim’s adalimumab biosimilar candidate to Humira, BI 695501, has been accepted for regulatory review by both the FDA and the European Medicines Agency (EMA).
The applications for FDA and EMA approvals are supported by top-line results from the completed Phase III study of BI 695501 that were announced in October 2016, which was conducted in patients with active rheumatoid arthritis (RA), according to Boehringer Ingelheim. [www.boehringer-ingelheim.us/press-release/boehringer-ingelheims-adalimumab-biosimilar-candidate-shows-similar-efficacy-and] The results of the study showed that BI 695501 met the clinical study efficacy end points to establish equivalence with Humira in patients with active RA and also met the secondary end points for the efficacy, safety, and immunogenicity of BI 695501 versus Humira.
The Phase III study was a randomized, double-blind, parallel arm, multiple dose, active comparator study in 645 patients diagnosed with moderate to severe active RA who were treated with methotrexate. Each participant was randomized to either BI 695501 or Humira every 2 weeks for 48 weeks. Efficacy was measured in patients with RA by ascertaining the proportion of patients with RA who met American College of Rheumatology 20 (ACR20) criteria at week 12 and week 24 compared with baseline.
If approved, BI 695501 can offer a high-quality, economically sustainable treatment option to patients with inflammatory diseases, said Martina Flammer, Vice President, Clinical Development and Medical Affairs, Specialty Care, at Boehringer Ingelheim, and would be a critical milestone for the company as it seeks to expand treatment options for patients with biosimilars.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action
April 22nd 2024Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.